10 research outputs found

    Corrosion Inhibitors

    No full text
    Advances in the field of corrosion inhibitors proceed in two main directions: (i) development of eco-friendly effective treatments and (ii) production of "smart” coatings. The first issue is connected to the more strict regulations regarding corrosion inhibitors application, due to environmental concerns. As a consequence, in various fields spanning from cooling water treatments, oil and gas production and transportation, acid media processes, protective coatings and reinforced concrete structures, research efforts have produced new nontoxic (or less toxic) effective formulations, often taking advantage of synergistic inhibiting effects between different substances and in some cases based on nonhazardous natural products. The recent advances in the field of nanotechnologies have triggered the development of more long-lasting inhibitor-containing coatings. The technology of “smart” corrosion inhibitor release, now also tentatively applied to solutions simulating concrete pore electrolyte, involves preparation of nano- or microcontainers of inhibiting substances, capable to release them in the coating/in concrete just when and where corrosion starts

    Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia

    Get PDF
    Positron emission tomography (PET) imaging with radiotracers that target translocator protein 18 kDa (TSPO) has become a popular approach to assess putative neuroinflammatory processes and associated microglia activation in psychotic illnesses. It remains unclear, however, whether TSPO imaging can accurately capture low-grade inflammatory processes such as those present in schizophrenia and related disorders. Therefore, we evaluated the validity of TSPO as a disease-relevant marker of inflammation using a translational approach, which combined neurodevelopmental and neurodegenerative mouse models with PET imaging in patients with recent-onset schizophrenia and matched controls. Using an infection-mediated neurodevelopmental mouse model, we show that schizophrenia-relevant behavioral abnormalities and increased inflammatory cytokine expression are associated with reduced prefrontal TSPO levels. On the other hand, TSPO was markedly upregulated in a mouse model of acute neurodegeneration and reactive gliosis, which was induced by intrahippocampal injection of kainic acid. In both models, the changes in TSPO levels were not restricted to microglia but emerged in various cell types, including microglia, astrocytes and vascular endothelial cells. Human PET imaging using the second-generation TSPO radiotracer [(11)C]DPA-713 revealed a strong trend towards reduced TSPO binding in the middle frontal gyrus of patients with recent-onset schizophrenia, who were previously shown to display increased levels of inflammatory cytokines in peripheral and central tissues. Together, our findings challenge the common assumption that central low-grade inflammation in schizophrenia is mirrored by increased TSPO expression or ligand binding. Our study further underscores the need to interpret altered TSPO binding in schizophrenia with caution, especially when measures of TSPO are not complemented with other markers of inflammation. Unless more selective microglial markers are available for PET imaging, quantification of cytokines and other inflammatory biomarkers, along with their molecular signaling pathways, may be more accurate in attempts to characterize inflammatory profiles in schizophrenia and other mental disorders that lack robust reactive gliosis

    Brain microglia in psychiatric disorders

    No full text
    Summary The role of immune activation in psychiatric disorders has attracted considerable attention over the past two decades, contributing to the rise of a new era for psychiatry. Microglia, the macrophages of the brain, are progressively becoming the main focus of the research in this field. In this Review, we assess the literature on microglia activation across different psychiatric disorders, including post-mortem and in-vivo studies in humans and experimental studies in animals. Although microglia activation has been noted in all types of psychiatric disorder, no association was seen with specific diagnostic categories. Furthermore, the findings from these studies highlight that not all psychiatric patients have microglial activation. Therefore, the cause of the neuroinflammation in these cohorts and its implications are unclear. We discuss psychosocial stress as one of the main factors determining microglial activation in patients with psychiatric disorders, and explore the relevance of these findings for future treatment strategies
    corecore